{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:52:43Z","timestamp":1781617963557,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The American Academy of Pediatrics recommended the use of pre-discharge delta total bilirubin (DeltaTB) to determine appropriate follow-up timing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine the proportion of neonates requiring post-discharge phototherapy after applying the pre-discharge DeltaTB approach, and to assess its effectiveness in predicting phototherapy needs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a prospective cohort study conducted at Chiang Mai University Hospital. The pre-discharge DeltaTB, defined as the difference between the bilirubin level and the phototherapy threshold at the time of measurement. Based on pre-discharge DeltaTB (mg\/dL), patients were categorized into 3 risk groups: high-risk (&lt;\u20093.5), moderate risk (3.5\u20136.9) and low risk (&gt;\u20097). Post-discharge phototherapy, pre-discharge TB, and number of follow-up were compared between the risk groups. DeltaTB levels in different age intervals were analyzed using ROC curve analysis to determine the cutoff in each interval.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Out of 150 neonates, 31 (20.6%) required post-discharge phototherapy, with 9 (6.0%) neonates were classified as requiring subthreshold phototherapy. There were 17.3%, 53.3% and 19.3% of 150 neonates categorized as high, moderate, and low risk by pre-discharge DeltaTB, respectively. The high-risk group, had the highest proportion of post-discharge phototherapy, mean pre-discharge bilirubin level and number of follow-up visits and were significantly different from other groups (\n                      <jats:italic>P-value<\/jats:italic>\n                      \u2009&lt;\u20090.001). The optimal timing for measuring pre-discharge bilirubin was aged 49\u201372\u00a0h (AUC of 0.851).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pre-discharge DeltaTB effectively stratified neonates by risk for post-discharge phototherapy and may guide timely follow-up to prevent severe hyperbilirubinemia, with significantly higher rates in the high-risk group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12887-025-06238-8","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:56:35Z","timestamp":1763135795000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The application of pre-discharge delta total bilirubin to predict the need for post-discharge phototherapy in healthy neonates 35 weeks\u2019 gestation or later"],"prefix":"10.1186","volume":"25","author":[{"given":"Thawinee","family":"Maneesilasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallika","family":"Pomrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"issue":"12","key":"6238_CR1","doi-asserted-by":"publisher","first-page":"699","DOI":"10.12968\/hmed.2017.78.12.699","volume":"78","author":"S Mitra","year":"2017","unstructured":"Mitra S, Rennie J. Neonatal jaundice: aetiology, diagnosis and treatment. Br J Hosp Med (Lond). 2017;78(12):699\u2013704.","journal-title":"Br J Hosp Med (Lond)"},{"key":"6238_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gpeds.2023.100131","volume":"7","author":"E Okulu","year":"2024","unstructured":"Okulu E. Neonatal jaundice: recommendations for follow-up and treatment. Glob Pediatr. 2024;7:100131.","journal-title":"Glob Pediatr"},{"issue":"4","key":"6238_CR3","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1542\/peds.2009-0329","volume":"124","author":"MJ Maisels","year":"2009","unstructured":"Maisels MJ, Bhutani VK, Bogen D, Newman TB, Stark AR, Watchko JF. Hyperbilirubinemia in the newborn infant\u2009>\u2009or =\u200935 weeks\u2019 gestation: an update with clarifications. Pediatrics. 2009;124(4):1193\u20138.","journal-title":"Pediatrics"},{"issue":"3","key":"6238_CR4","first-page":"e13685","volume":"13","author":"DS Khan","year":"2021","unstructured":"Khan DS, Mirza A, Bhatti A, Shabbir A, Tariq B, Rizvi A. Effectiveness of transcutaneous bilirubin measurement in high-risk neonates and to evaluate validity of transcutaneous bilirubin with total serum bilirubin levels in both low and high-risk neonates at a tertiary care center in a developing country. Cureus. 2021;13(3):e13685.","journal-title":"Cureus"},{"key":"6238_CR5","doi-asserted-by":"crossref","unstructured":"Kemper AR, Newman TB, Slaughter JL, Maisels MJ, Watchko JF, Downs SM, et al. Clinical practice guideline revision: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2022;150(3):e2022058859.","DOI":"10.1542\/peds.2022-058859"},{"issue":"1","key":"6238_CR6","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12887-020-02157-y","volume":"20","author":"A Blumovich","year":"2020","unstructured":"Blumovich A, Mangel L, Yochpaz S, Mandel D, Marom R. Risk factors for readmission for phototherapy due to jaundice in healthy newborns: a retrospective, observational study. BMC Pediatr. 2020;20(1):248.","journal-title":"BMC Pediatr"},{"key":"6238_CR7","doi-asserted-by":"publisher","DOI":"10.21037\/pm-21-4","author":"TWR Hansen","year":"2021","unstructured":"Hansen TWR. Narrative review of the epidemiology of neonatal jaundice. Pediatr Med. 2021. https:\/\/doi.org\/10.21037\/pm-21-4.","journal-title":"Pediatr Med"},{"key":"6238_CR8","doi-asserted-by":"publisher","DOI":"10.4103\/jcn.JCN_35_17","author":"N Rajan","year":"2017","unstructured":"Rajan N, Kumar Kommu PP, Krishnan L, Mani M. Significant hyperbilirubinemia in near-term and term newborns: a case\u2013control study. J Clin Neonatol. 2017. https:\/\/doi.org\/10.4103\/jcn.JCN_35_17.","journal-title":"J Clin Neonatol"},{"issue":"5","key":"6238_CR9","doi-asserted-by":"publisher","first-page":"e016050","DOI":"10.1136\/bmjopen-2017-016050","volume":"7","author":"C Battersby","year":"2017","unstructured":"Battersby C, Michaelides S, Upton M, Rennie JM. Term admissions to neonatal units in England: a role for transitional care? A retrospective cohort study. BMJ Open. 2017;7(5):e016050.","journal-title":"BMJ Open"},{"issue":"3","key":"6238_CR10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s12519-014-0495-8","volume":"10","author":"ZB Yu","year":"2014","unstructured":"Yu ZB, Han SP, Chen C. Bilirubin nomograms for identification of neonatal hyperbilirubinemia in healthy term and late-preterm infants: a systematic review and meta-analysis. World J Pediatr. 2014;10(3):211\u20138.","journal-title":"World J Pediatr"},{"issue":"10","key":"6238_CR11","doi-asserted-by":"publisher","first-page":"e0258127","DOI":"10.1371\/journal.pone.0258127","volume":"16","author":"L Thielemans","year":"2021","unstructured":"Thielemans L, Peerawaranun P, Mukaka M, Paw MK, Wiladphaingern J, Landier J, et al. High levels of pathological jaundice in the first 24 hours and neonatal hyperbilirubinaemia in an epidemiological cohort study on the Thailand-Myanmar border. PLoS ONE. 2021;16(10):e0258127.","journal-title":"PLoS ONE"},{"issue":"5","key":"6238_CR12","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/j.1365-3156.2010.02496.x","volume":"15","author":"SS Tikmani","year":"2010","unstructured":"Tikmani SS, Warraich HJ, Abbasi F, Rizvi A, Darmstadt GL, Zaidi AK. Incidence of neonatal hyperbilirubinemia: a population-based prospective study in Pakistan. Trop Med Int Health. 2010;15(5):502\u20137.","journal-title":"Trop Med Int Health"},{"issue":"9","key":"6238_CR13","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1056\/NEJMct0708376","volume":"358","author":"MJ Maisels","year":"2008","unstructured":"Maisels MJ, McDonagh AF. Phototherapy for neonatal jaundice. N Engl J Med. 2008;358(9):920\u20138.","journal-title":"N Engl J Med"},{"issue":"4","key":"6238_CR14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1385\/NMM:8:4:513","volume":"8","author":"JF Watchko","year":"2006","unstructured":"Watchko JF. Kernicterus and the molecular mechanisms of bilirubin-induced CNS injury in newborns. Neuromol Med. 2006;8(4):513\u201329.","journal-title":"Neuromol Med"},{"issue":"1","key":"6238_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1542\/peds.114.1.297","volume":"114","author":"American Academy of Pediatrics Subcommittee on H","year":"2004","unstructured":"American Academy of Pediatrics Subcommittee on H. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114(1):297\u2013316.","journal-title":"Pediatrics"},{"issue":"4","key":"6238_CR16","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.pcl.2004.03.011","volume":"51","author":"VK Bhutani","year":"2004","unstructured":"Bhutani VK, Johnson LH, Keren R. Diagnosis and management of hyperbilirubinemia in the term neonate: for a safer first week. Pediatr Clin North Am. 2004;51(4):843\u201361. vii.","journal-title":"Pediatr Clin North Am"},{"issue":"10","key":"6238_CR17","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1080\/14767058.2018.1527308","volume":"33","author":"W Tantiprabha","year":"2020","unstructured":"Tantiprabha W, Tiyaprasertkul W. Transcutaneous bilirubin nomogram for the first 144 hours in Thai neonates. J Matern Fetal Neonatal Med. 2020;33(10):1688\u201394.","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"4","key":"6238_CR18","first-page":"237","volume":"66","author":"K Booranavanich","year":"2022","unstructured":"Booranavanich K, Chakthranont N. Incidence and risks of readmission due to neonatal jaundice. Vajira Med Journal: J Urban Med. 2022;66(4):237\u201344.","journal-title":"Vajira Med Journal: J Urban Med"},{"issue":"1","key":"6238_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.70933\/2773-9465.1113","volume":"21","author":"S Prachukthum","year":"2021","unstructured":"Prachukthum S, Tanprasertkul C, Intarakhao S. Predictive factors for term infants with neonatal hyperbilirubinemia requiring readmission for phototherapy. Asian Med J Altern Med. 2021;21(1):14\u201320.","journal-title":"Asian Med J Altern Med"},{"key":"6238_CR20","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-019778","author":"MW Kuzniewicz","year":"2021","unstructured":"Kuzniewicz MW, Park J, Niki H, Walsh EM, McCulloch CE, Newman TB. Predicting the need for phototherapy after discharge. Pediatrics. 2021. https:\/\/doi.org\/10.1542\/peds.2020-019778.","journal-title":"Pediatrics"},{"issue":"4","key":"6238_CR21","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1001\/jamapediatrics.2017.5630","volume":"172","author":"AC Wickremasinghe","year":"2018","unstructured":"Wickremasinghe AC, Kuzniewicz MW, McCulloch CE, Newman TB. Efficacy of subthreshold newborn phototherapy during the birth hospitalization in preventing readmission for phototherapy. JAMA Pediatr. 2018;172(4):378\u201385.","journal-title":"JAMA Pediatr"},{"issue":"2","key":"6238_CR22","doi-asserted-by":"publisher","first-page":"180","DOI":"10.31524\/bkkmedj.2019.09.010","volume":"15","author":"S Kankaew","year":"2019","unstructured":"Kankaew S, Daramas T, Patoomwan A. Frequency of breastfeeding, bilirubin levels, and re-admission for jaundice in neonates. Bangkok Med J. 2019;15(2):180.","journal-title":"Bangkok Med J"},{"key":"6238_CR23","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023-063323","author":"L Sarathy","year":"2024","unstructured":"Sarathy L, Chou JH, Romano-Clarke G, Darci KA, Lerou PH. Bilirubin measurement and phototherapy use after the AAP 2022 newborn hyperbilirubinemia guideline. Pediatrics. 2024. https:\/\/doi.org\/10.1542\/peds.2023-063323.","journal-title":"Pediatrics"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-06238-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-025-06238-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-06238-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:00:16Z","timestamp":1781614816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12887-025-06238-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6238"],"URL":"https:\/\/doi.org\/10.1186\/s12887-025-06238-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6240272\/v1","asserted-by":"object"}]},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Research Ethics Committee of the Faculty of Medicine at Chiang Mai University (Study code: PED-2566-0283). Written informed consent was obtained from the parents or legal guardians of all participants before their enrollment in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and Consent to Participate\u00a0"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"930"}}